martes, 8 de julio de 2025

Cogent Biosciences drug improves symptoms of chronic immune disorder, study results show A comparison of the therapy to a rival treatment from Blueprint Medicines remains muddled

https://www.statnews.com/2025/07/07/cogent-biosciences-bezuclastinib-indolent-systemic-mastocytosis-blueprint-comparison/

No hay comentarios:

Publicar un comentario